Epigenomics AG (EPGNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Epigenomics AG (EPGNF) with AI Score 55/100 (Hold). Epigenomics AG focuses on developing and commercializing molecular diagnostic products for early cancer detection using liquid biopsy. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Epigenomics AG (EPGNF) Healthcare & Pipeline Overview
Epigenomics AG is a molecular diagnostics company specializing in liquid biopsy for early cancer detection, primarily through its Epi proColon blood test for colorectal cancer. With a focus on epigenetic biomarkers, the company aims to provide minimally invasive screening solutions in the US, Europe, and China, operating in a competitive diagnostics market.
Investment Thesis
Epigenomics AG presents a focused investment opportunity within the liquid biopsy and early cancer detection market. The company's Epi proColon test addresses a significant unmet need for convenient colorectal cancer screening, particularly among individuals who avoid traditional colonoscopies. However, the company's limited market capitalization of $0.00B and negative P/E ratio of -0.24, coupled with a high negative profit margin of -2479.2%, indicate substantial financial challenges. Growth catalysts include potential expansion into new geographic markets and the development of additional cancer screening tests. The company's success hinges on increasing market adoption of Epi proColon and achieving profitability.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and potential volatility.
- P/E Ratio of -0.24 indicates that the company is currently unprofitable.
- Profit Margin of -2479.2% highlights significant operational losses.
- Gross Margin of 75.3% suggests strong pricing power on existing sales, but is offset by high operating expenses.
- Beta of 0.84 indicates lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary epigenetic biomarker technology
- Epi proColon test addresses an unmet need for non-invasive colorectal cancer screening
- Established partnerships in key markets (US, Europe, China)
- Expertise in liquid biopsy and molecular diagnostics
Weaknesses
- Limited market capitalization and financial resources
- Negative profitability and high operating losses
- Reliance on a single product (Epi proColon)
- Competition from established diagnostic companies
Catalysts
- Ongoing: Increasing adoption of Epi proColon in the US, Europe, and China.
- Upcoming: Potential expansion into new geographic markets.
- Upcoming: Development and commercialization of new cancer screening tests.
- Ongoing: Strategic partnerships with healthcare providers to increase market access.
Risks
- Ongoing: Intense competition in the molecular diagnostics market.
- Potential: Regulatory hurdles and reimbursement challenges for diagnostic tests.
- Potential: Patent expiration and biosimilar competition for Epi proColon.
- Ongoing: Limited financial resources and negative profitability.
- Potential: Changes in healthcare policies and guidelines affecting cancer screening.
Growth Opportunities
- Expansion into New Geographic Markets: Epigenomics AG has the opportunity to expand the availability of Epi proColon into additional geographic markets beyond the United States, Europe, and China. Focusing on regions with high colorectal cancer incidence and limited access to traditional screening methods could drive significant revenue growth. The global market for colorectal cancer diagnostics is projected to reach billions of dollars, providing a substantial addressable market for Epigenomics AG.
- Development of Additional Cancer Screening Tests: Epigenomics AG can leverage its expertise in epigenetic biomarkers to develop and commercialize additional liquid biopsy tests for other types of cancer, such as lung cancer, breast cancer, and prostate cancer. Expanding the product portfolio would diversify revenue streams and reduce reliance on Epi proColon. The market for multi-cancer early detection tests is emerging and represents a significant growth opportunity.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with healthcare providers, such as hospitals, clinics, and physician groups, can facilitate the adoption of Epi proColon and other diagnostic tests. Collaborating with healthcare providers can improve market access, increase test utilization, and enhance brand awareness. These partnerships can also provide valuable insights into clinical needs and market trends.
- Increased Marketing and Awareness Campaigns: Investing in targeted marketing and awareness campaigns can educate both healthcare professionals and the general public about the benefits of Epi proColon and liquid biopsy for early cancer detection. Raising awareness can drive demand for the test and increase screening rates. Effective marketing strategies include online advertising, social media engagement, and participation in medical conferences.
- Advancements in Liquid Biopsy Technology: Continued advancements in liquid biopsy technology, such as improved sensitivity and specificity of biomarker detection, can enhance the performance and clinical utility of Epigenomics AG's diagnostic tests. Investing in research and development to refine the company's technology platform can maintain a competitive edge and attract new customers. These advancements can also lead to the development of more accurate and cost-effective screening solutions.
Opportunities
- Expansion into new geographic markets
- Development of additional cancer screening tests
- Strategic partnerships with healthcare providers
- Increased marketing and awareness campaigns
Threats
- Competition from alternative screening methods (colonoscopy, stool-based tests)
- Regulatory hurdles and reimbursement challenges
- Patent expiration and biosimilar competition
- Changes in healthcare policies and guidelines
Competitive Advantages
- Proprietary epigenetic biomarker technology.
- Patent protection for diagnostic tests and methods.
- Established market presence with Epi proColon.
- Expertise in liquid biopsy and molecular diagnostics.
About EPGNF
Founded in 1998 in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the development and commercialization of innovative liquid biopsy tests for early cancer detection. The company's core technology revolves around analyzing epigenetic biomarkers in blood samples to identify cancer signals at an early stage. Their flagship product, Epi proColon, is a blood-based screening test designed for the early detection of colorectal cancer. Epi proColon is currently available in the United States, Europe, and China, targeting individuals who are unwilling or unable to undergo traditional colonoscopy screening. Beyond Epi proColon, Epigenomics AG is also involved in the development of a blood test for hepatocellular carcinoma. The company also offers Epi BiSKit, a pre-analytical tool that provides reagents for bisulfite-converted DNA preparation, essential for epigenetic analysis. Epigenomics AG's research and development efforts are centered on identifying and validating novel biomarkers in human tissue, with the goal of developing and patenting corresponding in vitro diagnostic blood tests. The company aims to provide convenient and accessible cancer screening solutions, contributing to improved patient outcomes through early detection.
What They Do
- Develop and commercialize molecular diagnostic products for early cancer detection.
- Focus on liquid biopsy technology using blood samples.
- Offer Epi proColon, a blood-based test for colorectal cancer screening.
- Provide Epi BiSKit, a pre-analytical tool for bisulfite-converted DNA preparation.
- Conduct research and development to identify and validate novel biomarkers.
- Patent in vitro diagnostic blood tests.
Business Model
- Develop and patent diagnostic blood tests for early cancer detection.
- Commercialize these tests through direct sales and partnerships with healthcare providers.
- Generate revenue from the sale of Epi proColon and other diagnostic products.
- Offer pre-analytical tools like Epi BiSKit to support epigenetic analysis.
Industry Context
Epigenomics AG operates in the rapidly evolving molecular diagnostics market, specifically within the liquid biopsy segment. This market is driven by the increasing demand for non-invasive cancer screening methods and personalized medicine. The competitive landscape includes established diagnostic companies and emerging players focused on liquid biopsy technologies. Epigenomics AG's success depends on its ability to differentiate its Epi proColon test and gain market share in the colorectal cancer screening market, which is projected to grow significantly due to increasing cancer incidence and awareness.
Key Customers
- Individuals at risk for colorectal cancer who are unwilling or unable to undergo traditional colonoscopy.
- Healthcare providers, including hospitals, clinics, and physician groups.
- Laboratories that perform diagnostic testing.
- Research institutions conducting studies on cancer biomarkers.
Financials
Chart & Info
Epigenomics AG (EPGNF) stock price: Price data unavailable
Latest News
No recent news available for EPGNF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EPGNF.
Price Targets
Wall Street price target analysis for EPGNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates EPGNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Noel Thomas Doheny
Unknown
Information on Noel Thomas Doheny's background and career history is not available in the provided data.
Track Record: Information on Noel Thomas Doheny's track record and achievements is not available in the provided data.
EPGNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Epigenomics AG may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud or mismanagement compared to listed companies.
- OTC Other companies may not be subject to the same regulatory oversight as exchange-listed companies.
- Potential for delisting or trading suspensions due to non-compliance.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Understand the company's capital structure and any outstanding debt.
- Evaluate the company's competitive landscape and potential risks.
- Consult with a financial advisor before investing.
- Epi proColon is sold in US, Europe, and China.
- Focus on cancer diagnostics addresses a real market need.
- The company has been in operation since 1998.
- Gross margin of 75.3% suggests strong pricing power.
Common Questions About EPGNF
What does Epigenomics AG do?
Epigenomics AG is a molecular diagnostics company focused on developing and commercializing blood-based tests for early cancer detection. Their primary product, Epi proColon, is a blood test designed to screen for colorectal cancer in individuals who are unwilling or unable to undergo traditional colonoscopy. The company utilizes epigenetic biomarkers to identify cancer signals in blood samples, providing a minimally invasive alternative for cancer screening. Epigenomics AG aims to improve patient outcomes through early detection and convenient access to cancer screening solutions.
What do analysts say about EPGNF stock?
There is no analyst consensus available for EPGNF in the provided data. The company's financial metrics, including a negative P/E ratio and a high negative profit margin, suggest significant financial challenges. Investors should carefully consider the company's financial performance, growth prospects, and competitive landscape before making any investment decisions. Further research and due diligence are recommended to assess the potential risks and rewards associated with investing in EPGNF.
What are the main risks for EPGNF?
The main risks for Epigenomics AG include intense competition in the molecular diagnostics market, regulatory hurdles and reimbursement challenges for diagnostic tests, potential patent expiration and biosimilar competition for Epi proColon, limited financial resources and negative profitability, and changes in healthcare policies and guidelines affecting cancer screening. The company's reliance on a single product (Epi proColon) also poses a risk, as any setbacks in its commercialization or market acceptance could significantly impact the company's financial performance.
What are the key factors to evaluate for EPGNF?
Epigenomics AG (EPGNF) currently holds an AI score of 55/100, indicating moderate score. Key strength: Proprietary epigenetic biomarker technology. Primary risk to monitor: Ongoing: Intense competition in the molecular diagnostics market.. This is not financial advice.
How frequently does EPGNF data refresh on this page?
EPGNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EPGNF's recent stock price performance?
Recent price movement in Epigenomics AG (EPGNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary epigenetic biomarker technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EPGNF overvalued or undervalued right now?
Determining whether Epigenomics AG (EPGNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EPGNF?
Before investing in Epigenomics AG (EPGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- OTC Other stocks carry higher risk.